论文部分内容阅读
目的探讨阿托伐他汀联合辅酶Q10对慢性心力衰竭患者血清超敏C反应蛋白(high sensitivity C-reactive protein,hs-CRP)、内皮素-1(endothelin 1,ET-1)、脑钠肽(brain natriuretic peptide,BNP)的影响。方法自2013年1月—2015年1月收治的100例慢性心力衰竭患者依照数字随机分组法分为2组:对照组50例采用酒石酸美托洛尔+氯沙坦+螺内酯+阿托伐他汀治疗,观察组50例在对照组治疗方法上加用辅酶Q10,比较2组患者治疗前后hs-CRP、ET-1、BNP指标水平及心功能变化。结果观察组治疗有效率为94.0%,显著高于对照组(70.0%)(P<0.05);2组患者治疗后,hs-CRP、ET-1以及BNP水平较治疗前显著下降(P<0.05);且观察组hs-CRP、ET-1以及BNP水平明显低于对照组(P<0.05);2组患者治疗后,短轴缩短率以及LVEF较治疗前明显升高(P<0.05),左心室舒张末期直径较治疗前明显降低(P<0.05),且观察组短轴缩短率以及LVEF明显高于对照组,左心室舒张末期直径明显低于对照组,差异具有统计学意义(P<0.05)。观察组二次住院率明显低于对照组(P<0.05)。结论阿托伐他汀联合辅酶Q10治疗慢性心力衰竭患者,能够明显降低患者体内hs-CRP、ET-1以及BNP水平,改善患者心功能,疗效确切。
Objective To investigate the effects of atorvastatin combined with coenzyme Q10 on the expression of serum high sensitivity C-reactive protein (hs-CRP), endothelin 1 (ET-1), brain natriuretic peptide brain natriuretic peptide (BNP). Methods From January 2013 to January 2015, 100 patients with chronic heart failure were divided into two groups according to the digital randomization method: 50 patients in the control group were treated with metoprolol tartrate + losartan + spironolactone + atorvastatin Treatment and observation group 50 patients in the control group were treated with coenzyme Q10, hs-CRP, ET-1, BNP levels and cardiac function changes before and after treatment in two groups were compared. Results The effective rate of observation group was 94.0%, which was significantly higher than that of control group (70.0%) (P <0.05). The levels of hs-CRP, ET-1 and BNP in two groups were significantly decreased ), And the levels of hs-CRP, ET-1 and BNP in the observation group were significantly lower than those in the control group (P <0.05). After treatment, the short axis shortening rate and the LVEF in the two groups were significantly higher than those before treatment The left ventricular end-diastolic diameter was significantly lower than that before treatment (P <0.05), and the short axis shortening rate and LVEF of the observation group were significantly higher than those of the control group. The diameter of the left ventricular end-diastole was significantly lower than that of the control group (P < 0.05). The second admission rate in observation group was significantly lower than that in control group (P <0.05). Conclusions Atorvastatin combined with coenzyme Q10 in patients with chronic heart failure can significantly reduce the level of hs-CRP, ET-1 and BNP in patients, and improve the cardiac function in patients with definite curative effect.